# Phase 1 Study of SAR440894 vs Placebo

> **NCT04441905** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 42 (actual)

## Conditions studied

- Chikungunya Virus Infection

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** SAR440894

## Key facts

- **NCT ID:** NCT04441905
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-14
- **Primary completion:** 2024-08-22
- **Final completion:** 2024-08-22
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04441905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04441905, "Phase 1 Study of SAR440894 vs Placebo". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04441905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*